Related Experiment Video
Updated: May 11, 2026
07:30
Assessing Insulin Clearance in Mice via In Situ Liver Perfusion
Published on: December 13, 2024
Hepatoselectivity and the evolution of insulin
R Herring1, R H Jones, D L Russell-Jones
1Centre for Endocrinology, Diabetes and Research, Royal Surrey County Hospital, Guildford, UK.
Diabetes, Obesity & Metabolism
|May 18, 2013
Summary
New hepatoselective insulin analogues aim to improve diabetes management by mimicking natural insulin action. These advanced insulins may reduce risks of hypoglycemia, weight gain, and long-term complications.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Despite advancements in insulin therapy, challenges persist in daily diabetes management and mitigating long-term complications.
- Current insulin treatments present a significant difference in liver versus peripheral tissue exposure compared to normal physiology.
- Microvascular and macrovascular complications remain leading causes of morbidity and mortality in both type 1 and type 2 diabetes.
Purpose of the Study:
- To explore the therapeutic potential of hepatoselective insulin analogues over existing insulin preparations.
- To discuss how hepatoselective insulins could address limitations of current diabetes management strategies.
- To examine the evolution and strategies for developing hepatoselective insulins.
Main Methods:
- Review of current insulin treatment limitations and physiological insulin action.
- Discussion of the concept and potential benefits of hepatoselective insulin analogues.
- Exploration of strategies for designing and creating hepatoselective insulins.
Main Results:
- Hepatoselective insulin analogues have the potential to restore the physiological hepatic-to-peripheral insulin action gradient.
- Potential benefits include reduced risk of hypoglycemia and weight gain.
- Possible reduction in microvascular and macrovascular complications associated with diabetes.
Conclusions:
- Hepatoselective insulin analogues represent a promising therapeutic strategy for improving diabetes care.
- Restoring normal insulin gradients may lead to better patient outcomes and fewer complications.
- Further research and development in creating these targeted insulin therapies are warranted.
Related Concept Videos
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:05Insulin Secretory Vesicles
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...